# SAM #75N95022C00004 NIDA continuation of preclinical medication discovery and abuse-liability testing **Buyer:** NIH Office of Logistics and Acquisition Operations **Posted:** November 13, 2026 **Respond By:** November 27, 2026 **Identifier:** 75N95022C00004 **NAICS:** 541715 The National Institute on Drug Abuse plans to continue its medication-discovery and abuse-liability research program through a noncompetitive contract modification. - **Government buyer:** National Institute on Drug Abuse (NIDA), within the National Institutes of Health (NIH); Addiction Treatment Discovery Program, Division of Therapeutics and Medical Consequences. - **Requested service:** Continue the Preclinical Medications Discovery and Abuse Liability Testing program, supporting therapeutic development for preclinical and clinical trials. - **Notable requirement:** Maintain continuity of ongoing research while a follow-on contract is planned and competed. - **OEMs and vendors:** No manufacturers, vendors, or contract performers are named. - **Procurement status:** This notice is not a request for competitive proposals; interested parties may provide capability information. ### Description

NOTICE OF A PROPOSED CONTRACT ACTION NON-COMPETITIVE

  1. Notice ID: 75N95022C00004
  2. Contract Opportunity Type: Presolicitation
  3. Response Date: November 27, 2026, at 1:00 PM Eastern Time (15 days)
  4. Classification: No Small Business Set Aside Used
  5. Product Service Code: AN11
  6. NAICS Code: 541715
  7. Place of Performance: Blank

Description

PURSUANT TO RFO 5.101 — PRESOLICITATION NOTICE, THIS IS A NOTICE OF A PROPOSED CONTRACT ACTION.   

THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE MODIFICATION UNDER CONTRACT NO. 75N95022C00004 WITH VIRGINIA COMMONWEALTH UNIVERSITY.  THIS IS NOT A SOLICITATION OR A REQUEST FOR COMPETITIVE PROPOSALS.

The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), through the Addiction Treatment Discovery Program (ATDP) within NIDA’s Division of Therapeutics and Medical Consequences (DTMC), intends to modify Single Award Contract No. 75N95022C00004, “Preclinical Medications Discovery and Abuse Liability Testing for NIDA,” to extend the period of performance by 12-months through February 21, 2027. All other terms and conditions remain unchanged.

This modification will allow for the continuation of ongoing research conducted under the Preclinical Medications Discovery and Abuse Liability Testing program for NIDA and prevent any delays or disruption to the development of therapeutics essential for ongoing and upcoming pre-clinical and clinical trials while a new contract is properly planned and competed. 

REGULATORY AUTHORITY

The resultant modification will include all applicable provisions and clauses of the Revolutionary FAR Overhaul (RFO) Initiative, in accordance with Executive Order 14275 and OMB Memorandum M-25-26.

STATUTORY AUTHORITY

This modification is conducted under the authority of 41 U.S.C. 3304(a)(1) and in accordance with RFO 6.103-1 Only one responsible source and no other supplies or services will satisfy agency requirements.

CLOSING STATEMENT

THIS IS NOT A REQUEST FOR COMPETITIVE PROPOSALS. However, interested parties may identify their interest and capability to respond to this notice.

A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. All responsible sources may submit a capability statement, proposal, or quotation which shall be considered by the agency. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement.

Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Unique Entity ID (UEI), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.

All responses must be received by the closing date and time of this announcement and must reference the Project Title, “Preclinical Medications Discovery and Abuse Liability Testing for NIDA.”  Responses must be submitted electronically to Shayna Simpson, Contracting Officer, at shayna.simpson@nih.gov. Mailed and faxed responses will not be accepted.

PRIMARY POINT OF CONTACT:

Shayna Simpson

Email: shayna.simpson@nih.gov

Phone: 301-402-9712

[View original listing](https://sam.gov/opp/54f02db654c1489dadd4275bbb1462d9/view)